BioCentury | Sep 17, 2020
Product Development

Sept. 16 Quick Takes: AAT deficiency data lift Arrowhead; plus Metacrine’s IPO, Seer spinout and PDUFA dates for Niemann-Pick, burn therapies

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | May 6, 2020
Management Tracks

Mendel named GenMark’s CEO; plus SutroVax, Illumina, Arrowhead, Tessa and more

GenMark Diagnostics Inc. (NASDAQ:GNMK) said interim president and CEO Scott Mendel will now serve in those roles full-time. He joined the company as CFO in 2014 and became COO in 2019. The diagnostic company’s PCR-based...
BioCentury | Dec 7, 2019
Clinical News

Bladder cancer data poise FerGene gene therapy to compete with Keytruda

Less than two weeks after its launch, Ferring’s gene therapy subsidiary has revealed data that suggest its nadofaragene firadenovec could compete with Keytruda in an early form of bladder cancer. The adenovirus serotype 5 vector...
BioCentury | Aug 2, 2019
Company News

Aug. 1 Management tracks: R&D chief leaving Adaptimmune; plus Frontier Medicines builds out team and more

Adrian Rawcliffe, the incoming CEO of Adaptimmune Therapeutics plc (NASDAQ:ADAP), said Rafael Amado is leaving the T cell therapy company as president of R&D, effective Aug. 12, to pursue other opportunities. Rawcliffe also announced the...
BioCentury | Aug 2, 2019
Finance

Earnings on deck

Earnings on deck At least 14 profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket in New York; during market hours in Tel Aviv Company Date Pre/post mkt 2Q19 EPS est...
BioCentury | May 3, 2019
Finance

Earnings on deck

Earnings on deck At least 22 profitable biotechs and pharmas are slated to report earnings this week. (A) During trading hours in Europe; premarket on U.S. exchange; (B) Fiscal 4Q; Company Date Pre/post mkt 1Q19...
BioCentury | May 2, 2019
Company News

May 2 Company Quick Takes: Agios, Celgene/Presage, Purdue, Amgen/Syapse

Label expansion in AML for Agios’ Tibsovo FDA approved an sNDA for Tibsovo ivosidenib from Agios Pharmaceuticals Inc. (NASDAQ:AGIO) as monotherapy for adults with newly diagnosed acute myelogenous leukemia (AML) with a susceptible isocitrate dehydrogenase...
BioCentury | Mar 9, 2019
Regulation

Gottlieb’s exit interview

FDA Commissioner Scott Gottlieb sat down with BioCentury after announcing his resignation to discuss his approach to promoting medical product innovation, the importance of strategic communications, and how a reorganization will bring FDA drug reviews...
BioCentury | Feb 22, 2019
Finance

Earnings on deck

Earnings on deck At least 12 profitable biotechs and pharmas are slated to report earnings this week. (A) Six-month EPS Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg Corcept Therapeutics Inc. (NASDAQ:CORT)...
Items per page:
1 - 10 of 898